Marianne Hinkula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marianne Hinkula has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Antti Kauppila
5 shared publicationsEero Pukkala
4 shared publications- Esa Läärä
Research Unit of Mathematical Sciences, University of Oulu, Oulu, Finland
3 shared publications - Martti Arffman
Department of Health and Social Care Systems, National Institute for Health and Welfare, Helsinki, Finland
3 shared publications - Mikko Marttila
Children, Adolescents and Families Unit, Department of Welfare, National Institute for Health and Welfare, P.O. Box 310, FIN-90101 Oulu, Finland
3 shared publications Pentti Kyyrönen
3 shared publications
Latest Publications
- Open Access
- 28 July 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study
Ovarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even poorer survival from it. We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with metformin, other forms of antidiabetic medication, or statins. Study cohort consisted of women with T2D diagnosed with ovarian cancer in Finland 1998–2011. They were identified from a nationwide diabetes database (FinDM), being linked to several national registers. Patients were grouped according to their medication in the three years preceding ovarian cancer diagnosis. The Aalen–Johansen estimator was used to describe cumulative mortality from ovarian cancer and from other causes in different medication groups. Mortality rates were analysed by Cox models, and adjusted hazard ratios (HR) with 95% confidence intervals (95% CIs) were estimated in relation to the use of different forms of medication. Main outcome measures were death from ovarian cancer and death from other causes. During the accrual period 421 newly diagnosed ovarian cancers were identified in the FinDM database. No evidence was found for any differences in mortality from ovarian cancer or other causes between different antidiabetic medication groups. Pre-diagnostic use of statins was observed to be associated with decreased mortality from ovarian cancer compared with no such use (HR 0.72, 95% CI 0.56–0.93). Our findings are inconclusive as regards the association between metformin and ovarian cancer survival. However, some evidence was found for improved prognosis of ovarian cancer with pre-diagnostic statin use, requiring cautious interpretation, though.
- 28 July 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Open AccessPrognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study
Ovarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even poorer survival from it. We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with metformin, other forms of antidiabetic medication, or statins. Study cohort consisted of women with T2D diagnosed with ovarian cancer in Finland 1998–2011. They were identified from a nationwide diabetes database (FinDM), being linked to several national registers. Patients were grouped according to their medication in the three years preceding ovarian cancer diagnosis. The Aalen–Johansen estimator was used to describe cumulative mortality from ovarian cancer and from other causes in different medication groups. Mortality rates were analysed by Cox models, and adjusted hazard ratios (HR) with 95% confidence intervals (95% CIs) were estimated in relation to the use of different forms of medication. Main outcome measures were death from ovarian cancer and death from other causes. During the accrual period 421 newly diagnosed ovarian cancers were identified in the FinDM database. No evidence was found for any differences in mortality from ovarian cancer or other causes between different antidiabetic medication groups. Pre-diagnostic use of statins was observed to be associated with decreased mortality from ovarian cancer compared with no such use (HR 0.72, 95% CI 0.56–0.93). Our findings are inconclusive as regards the association between metformin and ovarian cancer survival. However, some evidence was found for improved prognosis of ovarian cancer with pre-diagnostic statin use, requiring cautious interpretation, though.
- Open Access
- 1 December 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (3) , 678-683
Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication
- 1 December 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (3) , 678-683
Open AccessCause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication
- Open Access
- 1 September 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 146 (3) , 636-641
Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes
- 1 September 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 146 (3) , 636-641
Open AccessAntidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes
- 30 December 2013
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 93 (2) , 221
P. J.Di Saia, W. T.Creasman (Editors). Clinical Gynecologic Oncology, 8th edition. Expert Consult online and print. Saunders Elsevier Inc., Philadelphia, PA, 2012. 708 pages. ISBN 978-0-323-07419-3. Price €129.
- 30 December 2013
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 93 (2) , 221
P. J.Di Saia, W. T.Creasman (Editors). Clinical Gynecologic Oncology, 8th edition. Expert Consult online and print. Saunders Elsevier Inc., Philadelphia, PA, 2012. 708 pages. ISBN 978-0-323-07419-3. Price €129.
- 1 January 2007
- Vol. 123 (9) , 1057-64
[Not Available].
- 1 October 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 103 (1) , 207-211
Incidence of ovarian cancer of grand multiparous women—A population-based study in Finland
- 1 October 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 103 (1) , 207-211
Incidence of ovarian cancer of grand multiparous women—A population-based study in Finland
- Open Access
- 21 December 2005
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 163 (4) , 367-373
Cause-specific Mortality of Grand Multiparous Women in Finland
Knowledge is limited on mortality of grand multiparous women (≥5 deliveries), whose hormonal, metabolic, and social conditions differ from the average. The authors studied overall and cause-specific mortality in 1974–2001 among 87,922 grand multiparous women including 3,678 grand grand multiparous women (≥10 deliveries) in Finland. Standardized mortality ratios were defined as ratios of observed to expected numbers of deaths, both derived from national cause-of-death files. During follow-up, 18,870 grand multiparous women and 625 grand grand multiparous women died (standardized mortality ratios (SMRs) = 0.95 and 1.01, respectively). Decreased mortality among grand multiparous women was found for cancers of the breast (SMR = 0.64, 95% confidence interval (CI): 0.59, 0.69), corpus uteri (SMR = 0.68, 95% CI: 0.56, 0.80), ovary (SMR = 0.68, 95% CI: 0.60, 0.75), bladder (SMR = 0.59, 95% CI: 0.41, 0.82), and respiratory tract (SMR = 0.80, 95% CI: 0.72, 0.88). The only malignant tumor associated with elevated mortality was kidney cancer (SMR = 1.38, 95% CI: 1.21, 1.56). The standardized mortality ratio was also low for dementia (SMR = 0.78, 95% CI: 0.72, 0.84), respiratory diseases (SMR = 0.80, 95% CI: 0.75, 0.85), and accidents and violent causes (SMR = 0.79, 95% CI: 0.73, 0.84). Mortality from diabetes mellitus (SMR = 1.42, 95% CI: 1.29, 1.55) and ischemic heart disease (SMR = 1.10, 95% CI: 1.08, 1.13) was increased. According to this study, overall mortality among grand multiparous women is not elevated. Low mortality from cancers is offset by higher mortality from cardiovascular conditions and diabetes mellitus.
- 21 December 2005
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 163 (4) , 367-373
Open AccessCause-specific Mortality of Grand Multiparous Women in Finland
Knowledge is limited on mortality of grand multiparous women (≥5 deliveries), whose hormonal, metabolic, and social conditions differ from the average. The authors studied overall and cause-specific mortality in 1974–2001 among 87,922 grand multiparous women including 3,678 grand grand multiparous women (≥10 deliveries) in Finland. Standardized mortality ratios were defined as ratios of observed to expected numbers of deaths, both derived from national cause-of-death files. During follow-up, 18,870 grand multiparous women and 625 grand grand multiparous women died (standardized mortality ratios (SMRs) = 0.95 and 1.01, respectively). Decreased mortality among grand multiparous women was found for cancers of the breast (SMR = 0.64, 95% confidence interval (CI): 0.59, 0.69), corpus uteri (SMR = 0.68, 95% CI: 0.56, 0.80), ovary (SMR = 0.68, 95% CI: 0.60, 0.75), bladder (SMR = 0.59, 95% CI: 0.41, 0.82), and respiratory tract (SMR = 0.80, 95% CI: 0.72, 0.88). The only malignant tumor associated with elevated mortality was kidney cancer (SMR = 1.38, 95% CI: 1.21, 1.56). The standardized mortality ratio was also low for dementia (SMR = 0.78, 95% CI: 0.72, 0.84), respiratory diseases (SMR = 0.80, 95% CI: 0.75, 0.85), and accidents and violent causes (SMR = 0.79, 95% CI: 0.73, 0.84). Mortality from diabetes mellitus (SMR = 1.42, 95% CI: 1.29, 1.55) and ischemic heart disease (SMR = 1.10, 95% CI: 1.08, 1.13) was increased. According to this study, overall mortality among grand multiparous women is not elevated. Low mortality from cancers is offset by higher mortality from cardiovascular conditions and diabetes mellitus.
- Open Access
- 2 March 2004
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (5) , 1025-1029
A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland
Previous studies suggest that high parity increases the risk of cervical cancer. We studied the risk of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN3) in a Finnish cohort of grand multiparous (GM) women (at least five children) with low prevalence of sexually transmitted infections (STI). The Finnish Cancer Registry data revealed 220 CC and 178 CIN3 cases among 86 978 GM women. Standardised incidence ratios (SIR) were calculated from the numbers of observed and expected cases. Interval analyses by parity, age at first birth and average birth interval were done using multivariate Poisson regression. Seroprevalence of human papillomavirus (HPV) 16 and Chlamydia trachomatis was tested among 561 GM women and 5703 women with 2–4 pregnancies. The incidence among GM women was slightly above the national average for squamous cell carcinoma of cervix uteri (SIR 1.21, 95% CI 1.05–1.40) and CIN3 (1.37, 95% CI 1.17–1.58), but lower for adenocarcinoma (SIR 0.77, 95% CI 0.52–1.10). The seroprevalence of HPV16 and Chlamydia trachomatis among GM women was lower than in the reference population, except among those women who had their child under age 19. Age under 20 years at first birth increased the risk of CC and CIN3 especially in premenopausal GM women, while increasing parity had no effect. The small relative risks of CC and CIN3 among GM women in our study as compared to studies from other countries can be explained by the exceptionally low prevalence of STIs in Finnish GM women. The observed SIRs between 1.2 and 1.4 should be interpreted to represent increased risk attributable to grand multiparity. The increased incidence of CC and CIN3 among young GM women suggests causal association to HPV 16 and Chlamydia trachomatis infections.
- 2 March 2004
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (5) , 1025-1029
Open AccessA population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland
Previous studies suggest that high parity increases the risk of cervical cancer. We studied the risk of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN3) in a Finnish cohort of grand multiparous (GM) women (at least five children) with low prevalence of sexually transmitted infections (STI). The Finnish Cancer Registry data revealed 220 CC and 178 CIN3 cases among 86 978 GM women. Standardised incidence ratios (SIR) were calculated from the numbers of observed and expected cases. Interval analyses by parity, age at first birth and average birth interval were done using multivariate Poisson regression. Seroprevalence of human papillomavirus (HPV) 16 and Chlamydia trachomatis was tested among 561 GM women and 5703 women with 2–4 pregnancies. The incidence among GM women was slightly above the national average for squamous cell carcinoma of cervix uteri (SIR 1.21, 95% CI 1.05–1.40) and CIN3 (1.37, 95% CI 1.17–1.58), but lower for adenocarcinoma (SIR 0.77, 95% CI 0.52–1.10). The seroprevalence of HPV16 and Chlamydia trachomatis among GM women was lower than in the reference population, except among those women who had their child under age 19. Age under 20 years at first birth increased the risk of CC and CIN3 especially in premenopausal GM women, while increasing parity had no effect. The small relative risks of CC and CIN3 among GM women in our study as compared to studies from other countries can be explained by the exceptionally low prevalence of STIs in Finnish GM women. The observed SIRs between 1.2 and 1.4 should be interpreted to represent increased risk attributable to grand multiparity. The increased incidence of CC and CIN3 among young GM women suggests causal association to HPV 16 and Chlamydia trachomatis infections.
- 8 February 2002
- Published by Wiley in International Journal of Cancer
- Vol. 98 (6) , 912-915
Grand multiparity and incidence of endometrial cancer: A population‐based study in Finland
The hormonal background of endometrial cancer is insufficiently characterised. We investigated the significance of parity, age at first birth, intensity between births, length of time from the first to the last birth and length of delivery‐free premenopausal period in a cohort of grand multiparous (GM) women, i.e., women with at least 5 births. Data of the Population Register of Finland (86,978 GM‐women) and the population‐based Finnish Cancer Registry were combined. Standardised incidence ratios (SIRs) were calculated by dividing the number of observed cancer cases by the expected number based on the national incidence rates. Multivariate relative risks (RRs) were estimated by Poisson regression analysis. The SIR for endometrial cancer among GM‐women was low [419 cases; SIR=0.57, 95% confidence interval (CI) 0.52–0.63]. The RR of endometrial cancer was 0.58 (95% CI 0.34–0.97) among women giving their first birth at an age of more than 30 years compared to women with first birth before the age of 20. In ages 50+ (94% of endometrial cancer cases), the RR for women with at least 8 births was 0.63 (95% CI 0.44–0.92) compared to those with 5 births, and those with a birth period of 20+ years had RR=0.57 (95% CI 0.34–0.96) compared to those with a period of <10 years, while prolonged average intensity between births showed only a small protective effect. The RR of endometrial cancer also correlated with the length of premenopausal delivery‐free period (RR = 0.61, 95% CI 0.44–0.86) for women with a short (15 years) period. Our findings, that a large number of births, old age at first birth, a long birth period and a short premenopausal delivery‐free period reduced the risk of postmenopausal endometrial cancer of GM‐women, emphasise the protective role of progesterone and the stimulatory role of estradiol in the hormonal background of this disease.
- 8 February 2002
- Published by Wiley in International Journal of Cancer
- Vol. 98 (6) , 912-915
Grand multiparity and incidence of endometrial cancer: A population‐based study in Finland
The hormonal background of endometrial cancer is insufficiently characterised. We investigated the significance of parity, age at first birth, intensity between births, length of time from the first to the last birth and length of delivery‐free premenopausal period in a cohort of grand multiparous (GM) women, i.e., women with at least 5 births. Data of the Population Register of Finland (86,978 GM‐women) and the population‐based Finnish Cancer Registry were combined. Standardised incidence ratios (SIRs) were calculated by dividing the number of observed cancer cases by the expected number based on the national incidence rates. Multivariate relative risks (RRs) were estimated by Poisson regression analysis. The SIR for endometrial cancer among GM‐women was low [419 cases; SIR=0.57, 95% confidence interval (CI) 0.52–0.63]. The RR of endometrial cancer was 0.58 (95% CI 0.34–0.97) among women giving their first birth at an age of more than 30 years compared to women with first birth before the age of 20. In ages 50+ (94% of endometrial cancer cases), the RR for women with at least 8 births was 0.63 (95% CI 0.44–0.92) compared to those with 5 births, and those with a birth period of 20+ years had RR=0.57 (95% CI 0.34–0.96) compared to those with a period of <10 years, while prolonged average intensity between births showed only a small protective effect. The RR of endometrial cancer also correlated with the length of premenopausal delivery‐free period (RR = 0.61, 95% CI 0.44–0.86) for women with a short (15 years) period. Our findings, that a large number of births, old age at first birth, a long birth period and a short premenopausal delivery‐free period reduced the risk of postmenopausal endometrial cancer of GM‐women, emphasise the protective role of progesterone and the stimulatory role of estradiol in the hormonal background of this disease.
- 1 August 2001
- Published by Springer Nature in Cancer Causes & Control
- Vol. 12 (6) , 491-500
Grand multiparity and the risk of breast cancer: population-based study in Finland
Objectives: The significance of reproductive factors on breast cancer risk has so far been characterized in populations with 5-paras as the highest category of parity. We extended these studies to a...
- 1 August 2001
- Published by Springer Nature in Cancer Causes & Control
- Vol. 12 (6) , 491-500
Grand multiparity and the risk of breast cancer: population-based study in Finland
Objectives: The significance of reproductive factors on breast cancer risk has so far been characterized in populations with 5-paras as the highest category of parity. We extended these studies to a...